[Use of Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs in Patients With COVID-19. The Agreed Experts' Position of Russian Society of Cardiology, Eurasian Association of Therapists, National Society on Atherothrombosis, Societies of Experts in Urgent Cardiology, Eurasian Arrhythmology Association]

Ye V Shlyakhto; G P Arutyunov; Yu N Belenkov; E I Tarlovskaya; A O Konradi; E P Panchenko; I S Yavelov; S N Tereshchenko; A V Ardashev; A G Arutyunov; N Yu Grigorieva; G A Dzhunusbekova; O M Drapkina; N A Koziolova; A L Komarov; E S Kropacheva; S V Malchikova; N P Mitkovskaya; Ya A Orlova; M M Petrova; A P Rebrov; H Sisakian; V V Skibitsky; A B Sugraliyev; I V Fomin; A I Chesnikova; I I Shaposhnik; E G Zhelyakov; S G Kanorskii; L V Kolotsey; V A Snezhitskiy

doi:10.18087/cardio.2020.6.n1180

[Use of Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs in Patients With COVID-19. The Agreed Experts' Position of Russian Society of Cardiology, Eurasian Association of Therapists, National Society on Atherothrombosis, Societies of Experts in Urgent Cardiology, Eurasian Arrhythmology Association]

Kardiologiia. 2020 May 25;60(6):1180. doi: 10.18087/cardio.2020.6.n1180.

[Article in Russian]

Authors

Ye V Shlyakhto¹, G P Arutyunov², Yu N Belenkov³, E I Tarlovskaya⁴, A O Konradi⁵, E P Panchenko⁶, I S Yavelov⁷, S N Tereshchenko⁶, A V Ardashev⁸, A G Arutyunov², N Yu Grigorieva⁴, G A Dzhunusbekova⁹, O M Drapkina¹⁰, N A Koziolova¹¹, A L Komarov¹², E S Kropacheva¹³, S V Malchikova¹⁴, N P Mitkovskaya¹⁵, Ya A Orlova⁸, M M Petrova¹⁶, A P Rebrov¹⁷, H Sisakian¹⁸, V V Skibitsky¹⁹, A B Sugraliyev²⁰, I V Fomin⁴, A I Chesnikova²¹, I I Shaposhnik²², E G Zhelyakov⁸, S G Kanorskii²³, L V Kolotsey²⁴, V A Snezhitskiy²⁴

Affiliations

¹ Almazov National Medical Research Centre of Ministry of Healthcare of Russia, Saint- Petersburg.
² Pirogov Russian National Research Medical University, Moscow.
³ First Moscow state medical University I. M. Sechenov, Moscow.
⁴ Volga Research Medical University, Nizhny Novgorod.
⁵ National research medical center V. A. Almazov of Ministry of Healthcare of Russia, Saint-Petersburg.
⁶ National Medical Research Center of Cardiology, Moscow.
⁷ National Medical Research Center for Therapy and Preventive Medicine, Moscow.
⁸ Lomonosov Moscow State University, Moscow.
⁹ Kazakh Medical University of Contnuing Education, Alma-Atyu.
¹⁰ National Center for Therapy and Preventive Medicine, Moscow.
¹¹ State funded educational institution of the highest education "E.A. Wagner Perm State Medical University" Public Health Ministry of Russian Federation, Perm.
¹² Department of clinical problems of atherothrombosis "NMIC cardiology" of the Ministry of health of the Russian Federation, Moscow.
¹³ National Medical Research Centre of Cardiology, Moscow.
¹⁴ Kirov State Medical University Kirov State Medical University, Kirov.
¹⁵ Cardiology and internal diseases of BSMU, Republic of Belarus, Minsk.
¹⁶ Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, Krasnoyarsk.
¹⁷ Saratov State Medical University named after V.I. Razumovsky, Saratov.
¹⁸ Yerevan State Medical University, Yerevan.
¹⁹ Cuban State Medical University, Krasnodar.
²⁰ Asfendiyarov Kazakh National Medical University, Alma-Atyu.
²¹ Rostov State Medical University, Rostov-on-Don.
²² South Ural state medical University, Chelyabinsk.
²³ Kuban State Medical University of the Ministry of Healthcare of the Russian Federation, Krasnodar.
²⁴ Grodno State Medical University, Grodno.

PMID: 32720611
DOI: 10.18087/cardio.2020.6.n1180

Abstract

This article discusses relevant aspects in the treatment of patients with COVID-19. Up-to-date information about principles for administration of statins, antithrombotics, and antiarrhythmics is presented. The authors addressed in detail specific features of reversing heart rhythm disorders in patients with coronavirus infection and the interaction of antiarrhythmic and antiviral drugs. Recommendations are provided for outpatient and inpatient antithrombotic therapy for patients with COVID-19. Issues of antithrombotic and antiviral drug interaction are discussed.

Publication types

Practice Guideline

MeSH terms

Anti-Arrhythmia Agents / therapeutic use
Anticoagulants* / therapeutic use
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Cardiology*
Coronavirus Infections* / drug therapy
Coronavirus Infections* / epidemiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Pandemics*
Pneumonia, Viral* / drug therapy
Pneumonia, Viral* / epidemiology
Russia
SARS-CoV-2
Societies, Medical

Substances

Anti-Arrhythmia Agents
Anticoagulants
Hydroxymethylglutaryl-CoA Reductase Inhibitors